Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 0 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Sun Pharma AI simulator
(@Sun Pharma_simulator)
Hub AI
Sun Pharma AI simulator
(@Sun Pharma_simulator)
Sun Pharma
Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team.
Sun Pharma was listed on the stock exchange in 1994 in an issue that was oversubscribed 55 times. The founding family continues to hold a majority stake in the company.
In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals. Other notable acquisitions include plants of Gujarat Lyka Organics (1996), MJ Pharma (1996), and Tamil Nadu Dadha Pharmaceuticals Limited (1997). Also in 1997, Sun Pharma initiated their first foray into the international market with the acquisition of Caraco Pharmaceuticals based in Detroit.
In 1998, Sun acquired a number of respiratory brands from Natco Pharma. It acquired Melmet Labs (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant in the US and Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008).
In 2010, the company acquired a controlling stake in Taro Pharmaceuticals, amongst the largest generic dermatology companies in the US, with operations across Canada and Israel.
In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals, a dermatology device company; and generics business of URL Pharma.
Sun Pharma
Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team.
Sun Pharma was listed on the stock exchange in 1994 in an issue that was oversubscribed 55 times. The founding family continues to hold a majority stake in the company.
In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals. Other notable acquisitions include plants of Gujarat Lyka Organics (1996), MJ Pharma (1996), and Tamil Nadu Dadha Pharmaceuticals Limited (1997). Also in 1997, Sun Pharma initiated their first foray into the international market with the acquisition of Caraco Pharmaceuticals based in Detroit.
In 1998, Sun acquired a number of respiratory brands from Natco Pharma. It acquired Melmet Labs (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant in the US and Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008).
In 2010, the company acquired a controlling stake in Taro Pharmaceuticals, amongst the largest generic dermatology companies in the US, with operations across Canada and Israel.
In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals, a dermatology device company; and generics business of URL Pharma.